Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial

Lancet

Volumn 364, Issue 9433, 2004, Pages 503-512

  Remuzzi, Giuseppe ^a,b   Lesti, Mariadomenica ^a   Gotti, Eliana ^b   Ganeva, Maria ^a,c   Dimitrov, Borislav D ^a,c   Ene Iordache, Bogdan ^a   Gherardi, Giulia ^a   Donati, Donato ^d   Salvadori, Maurizio ^e   Sandrini, Silvio ^f   Valente, Umberto ^g   Segoloni, Giuseppe ^h   Mourad, Georges ⁱ   Federico, Stefano ^j   Rigotti, Paolo ^k   Sparacino, Vito ^l   Bosmans, Jean Louis ^m   Perico, Norberto ^a   Ruggenenti, Piero ^a,b,n  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY HOSPITAL ST GEORGE   (Bulgaria)

^d OSPEDALE DI CIRCOLO   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SPEDALI CIVILI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k Ospedale Giustinianeo   (Italy)

^l Ospedale Civile Di Vicenza   (Italy)

^m UNIVERSITY OF ANTWERP   (Belgium)

ⁿ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG COST; DRUG EFFECT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; OLIGURIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLE SIZE; TABLET FORMULATION; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

EID: 4043144895     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16808-6     Document Type: Article

References (26)

1. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 51:1996;278-298
2. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443, a new, potent immunosuppressive agent. Transplantation. 51:1991;27-31
3. Salaman JR, Griffin PJA, Johnson RWG, et al. Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc. 25:1993;695-696
4. Deierhoi MH, Kaufman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS-61443) in renal transplantation at a single centre. Ann Surg. 217:1993;476-484
5. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
6. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029-1037
7. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321-1325
8. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 47:2000;215-245
9. Keown P, Niese D, on behalf of the International Sandimmun Neoral Study Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938-944.
10. Gaspari F, Perico N, Pisoni R, Anedda MF, Signorini O, Remuzzi G. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Clin Transplant. 12:1998;379-390
11. Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. Transplantation. 68:1999;1325-1331
12. Tejani A, Butt KMH, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation. 47:1989;229-233
13. Reisman L, Lieberman KV, Burrows L, Schanzer H. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation. 49:1990;76-80
14. Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation. 53:1992;1232-1235
15. Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation. 45:1988;53-55
16. Hricik DE, Mayers JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 18:1991;353-358
17. Hricik DE, Bartucci MR, Moir EJ, Mayers JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 51:1991;374-377
18. Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR. Prednisone withdrawal in HLA identical one haplotype-matched live-related and cadaveric renal transplant recipients. Kidney Int. 43(suppl):1993;S30-35
19. Hricik DE, O'Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 4:1993;1300-1305
20. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 11:2000;1910-1917
21. Ashan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Transplantation. 68:1999;1865-1874
22. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc. 20:(suppl 3):1988;121-125
23. Schulak J, Majers JT, Moritz CE, Hricik DE. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine treated renal transplant patients. Transplantation. 49:1990;327-332
24. Perna A, Gotti E, De Bernardis E, Perico N, Remuzzi G. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol. 7:1996;786-791
25. Perico N, Ruggenenti P, Gotti E, et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S, Trial. Kidney Int. 65:2004;1084-1090
26. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 69:2000;2405-2409